Predictive factors of antiparkinsonian drug reduction after subthalamic stimulation for parkinson’s disease

Kazuhiro Samura, Yasushi Miyagi, Minako Kawaguchi, Fumiaki Yoshida, Tsuyoshi Okamoto, Masatou Kawashima

Research output: Contribution to journalArticle

Abstract

Subthalamic nucleus deep brain stimulation (STN-DBS) improves motor symptoms in individuals with advanced Parkinson’s disease (PD) and enables physicians to reduce doses of antiparkinsonian drugs. We investigated possible predictive factors for the successful reduction of antiparkinsonian drug dosage after STN-DBS. We evaluated 33 PD patients who underwent bilateral STN-DBS. We assessed rates of reduction of the levodopa-equivalent daily dose (LEDD) and levodopa daily dose (LDD) by comparing drug doses before vs. 6-months post-surgery. We used correlation coefficients to measure the strength of the relationships between LEDD and LDD reduction rates and preoperative factors including age, disease duration, preoperative LEDD and LDD, unified Parkinson’s Disease Rating Scale part-II and -III, levodopa response rate, Mini-Mental State Examination score, dyskinesia score, Hamilton Rating Scale for depression, and the number of non-motor symptoms. The average LEDD and LDD reduction rates were 61.0% and 70.4%, respectively. Of the variables assessed, only the number of psychiatric/cognitive symptoms was significantly correlated with the LEDD reduction rate. No other preoperative factors were correlated with the LEDD or LDD reduction rate. A wide range of preoperative psychiatric and cognitive symptoms may predict the successful reduction of antiparkinsonian drugs after STN-DBS.

Original languageEnglish
Pages (from-to)331-336
Number of pages6
JournalNeurologia medico-chirurgica
Volume59
Issue number9
DOIs
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Predictive factors of antiparkinsonian drug reduction after subthalamic stimulation for parkinson’s disease'. Together they form a unique fingerprint.

  • Cite this